GLUT1

Wistar Scientists Discover New Immunosuppressive Mechanism in Brain Cancer

Retrieved on: 
fredag, maj 3, 2024
Cell, National Cancer Institute, Macrophage, Sapienza University of Rome, Genome, Glucose, Wistar Institute, Gene, Brain, Tumor microenvironment, Wistar, Metabolomics, Neuroscience, Immunity, Ben, Medical research, Microglia, Research, Proteomics, Immunology, Histone, Malignancy, Gene expression, Neoplasm, Aurelia, Cancer, Collaborative writing, DSM-IV codes, Prognosis, Immunosuppression, Immunotherapy, Duke School, Disease, GLUT1, Patient, Metabolism, Immune system, Angelica, Vaccine

The lab’s discovery was published in the paper, “ Glucose-driven histone lactylation promotes the immunosuppressive activity of monocyte-derived macrophages in glioblastoma ,” in the journal Immunity.

Key Points: 
  • The lab’s discovery was published in the paper, “ Glucose-driven histone lactylation promotes the immunosuppressive activity of monocyte-derived macrophages in glioblastoma ,” in the journal Immunity.
  • Indeed, monocyte-derived macrophages, but not microglia, blocked the activity of T cells (immune cells that destroy tumor cells), in preclinical models and patients.
  • Glioblastoma is inherently dangerous due to its location in the brain and its immunosuppressive tumor microenvironment, which renders glioblastoma resistant to promising immunotherapies.
  • Note: The work detailed in this publication was initiated at The H. Lee Moffitt Cancer Center during Dr. Veglia’s time there and continued at Wistar.

See How it's Done: Case Studies on Patient Experience Design, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
måndag, november 20, 2023
MPH, GLUT1 deficiency, CCRP, Diversity, Hearing, Patient, Patient experience, Draft Communications Data Bill, GLUT1, Pharmaceutical industry, Medical imaging

TORONTO, Nov. 20, 2023 /PRNewswire-PRWeb/ -- Designing clinical trials around the patient and their experience produces better trials, but what does that really mean, and how is it actually accomplished? How can you be sure you're collecting data of interest to patient communities? Many common strategies have minimal impact or inadvertently create new challenges for patients. If the trial doesn't work for patients in their everyday lives, then no recruitment or retention plan can guarantee your study will generate the data you need.

Key Points: 
  • In this free webinar, learn how to design trials with a patient experience approach.
  • The featured speakers will discuss how to consider data that is important to patient communities.
  • Attendees will examine a protocol for patient experience optimization and learn how to apply real-life examples to their study.
  • TORONTO, Nov. 20, 2023 /PRNewswire-PRWeb/ -- Designing clinical trials around the patient and their experience produces better trials, but what does that really mean, and how is it actually accomplished?

METAFORA’s Test for the Early Diagnosis of De Vivo Disease Recommended for Coverage by HAS

Retrieved on: 
onsdag, maj 3, 2023
Technology, Insurance, Neurology, Genetics, Health Technology, Professional Services, Software, Biotechnology, Health, Oncology, GLUT1 deficiency, GLUT1, Canadian National Calibration Reference Centre, Immaculata De Vivo, HAS, Pediatrics, Patient, Physician, Haute, Diagnosis, Hospital, Principal, Disease, Pharmaceutical industry, Medical imaging

METAFORA biosystems, today announces that the Haute Autorité de Santé (HAS), the French Health Technology Agency, has issued a recommendation for insurance coverage of METAglut1TM, a test for the early diagnosis of De Vivo disease (or GLUT1 deficiency syndrome), a rare neurometabolic disorder.

Key Points: 
  • METAFORA biosystems, today announces that the Haute Autorité de Santé (HAS), the French Health Technology Agency, has issued a recommendation for insurance coverage of METAglut1TM, a test for the early diagnosis of De Vivo disease (or GLUT1 deficiency syndrome), a rare neurometabolic disorder.
  • The HAS conducted a thorough evaluation of METAglut1TM, which included an assessment of its clinical performance and clinical utility.
  • The evaluation concluded that METAglut1 is a valuable addition to the diagnostic arsenal for Glut1 DS, and was ascribed a high clinical added value.
  • This rare neurometabolic disease is highly underdiagnosed, and we expect that METAglut1’s availability will increase awareness and help physicians to diagnose the disease earlier.

Kintara Therapeutics Presents Data at the 2022 American Association for Cancer Research Annual Meeting

Retrieved on: 
måndag, april 11, 2022
Private Securities Litigation Reform Act, Company, Cancer, Metabolism, Plasma, SGLT2, Sumathi Best Television Current Reporting Award, Ovary, Neck, Marketing, National Cancer Institute, Pharmacokinetics, GBM, Central nervous system, GLUT1, CNS, Research, SEC, CMBC, Head, SGLT1, PSA, Brain, NSCLC, Technology, BBB, COVID-19, Bladder cancer, NCI, Annual report, Glucose, National, Patient, Medical imaging, Pharmaceutical industry

Glucose transporters, in particular GLUT1, are overexpressed by the BBB since the brain requires very high concentrations of glucose for metabolism.

Key Points: 
  • Glucose transporters, in particular GLUT1, are overexpressed by the BBB since the brain requires very high concentrations of glucose for metabolism.
  • Laboratory studies presented at the meeting assessed whether glucose transporters are involved in the ability of VAL-083 to cross the BBB.
  • Located in San Diego, California, Kintara is dedicated to the development of novel cancer therapies for patients with unmet medical needs.
  • Kintara is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs.

ImmixBio Initiates GMP Manufacturing of IMX-120, a Biologic for Inflammatory Bowel Disease

Retrieved on: 
tisdag, februari 22, 2022
GLOBE, GMP, IBD, Ulcerative colitis, Neoplasm, LOS, PRV, GLUT1, Inflammatory Bowel Diseases, ODD, Industry, Company, TME, Inflammatory bowel disease, Rhabdomyosarcoma, Regulation, Biologics license application, IND, FDA, Good manufacturing practice, Cancer, Forward-looking statement, Patient, Marketing, MD, CEO, Vaccine, Pharmaceutical industry

LOS ANGELES, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “we” or “us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysregulated diseases, today announced that it has initiated Good Manufacturing Practice (“GMP”) manufacturing of IMX-120, a biologic for inflammatory bowel disease (“IBD”). ImmixBio anticipates filing an IND for IMX-120 in 2023, representing a significant milestone on ImmixBio’s path to clinical trials for IMX-120 in inflammatory bowel disease. The IBD market is expected to reach $21.4 billion by 2024 from the existing $18.4 billion in 2019.

Key Points: 
  • (Nasdaq: IMMX) (ImmixBio, Company, we or us),a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)targeting oncology and immuno-dysregulated diseases, today announced that it has initiated Good Manufacturing Practice (GMP) manufacturing of IMX-120, a biologic for inflammatory bowel disease (IBD).
  • ImmixBio anticipates filing an IND for IMX-120 in 2023, representing a significant milestone on ImmixBios path to clinical trials for IMX-120 in inflammatory bowel disease.
  • Initiating GMP manufacturing of IMX-120 represents a wholly new phase of development for ImmixBio as a biologics innovator, said Ilya Rachman, MD PhD, CEO of ImmixBio.
  • We believe this step is the beginning of a path toward a Biologics License Application (BLA) for IMX-120 in inflammatory bowel disease, including ulcerative colitis and Crohns disease.